Oculis Holding AG
NASDAQ: OCS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Riad Sherif
- Employees
- 49
- Headquarters
- Zug, Switzerland
- IPO year
- 2021
- Market cap
- $660.9M
- Website
- https://oculis.com
Loading OCS…
Loading profile data…Frequently asked questions about OCS
What does Oculis Holding AG (OCS) do?
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently pr...
Where does OCS trade?
Oculis Holding AG (OCS) trades on the NASDAQ Global Market.
What sector is OCS in?
Oculis Holding AG (OCS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Oculis Holding AG?
Riad Sherif is the chief executive officer of Oculis Holding AG (OCS).
Where is Oculis Holding AG headquartered?
Oculis Holding AG is headquartered in Switzerland.
Does OCS pay a dividend?
Oculis Holding AG (OCS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did OCS go public?
Oculis Holding AG (OCS) completed its initial public offering in 2021.